Literature DB >> 3537138

A solid-phase enzyme immunoassay for the determination of IgM and IgG antibodies against translation products of pre-S1 and pre-S2 regions of hepatitis B virus.

E Takai, A Machida, H Ohnuma, H Miyamoto, T Tanaka, K Baba, F Tsuda, S Usuda, T Nakamura, Y Miyakawa.   

Abstract

The envelope of hepatitis B virus is coded for by pre-S1, pre-S2 regions and the S gene. A method was developed to determine antibody to the product of pre-S1 region (anti-pre-S1) and antibody to the product of pre-S2 region (anti-pre-S2), either of IgM or IgG class, by a solid-phase enzyme immunoassay. For the determination of anti-pre-S1, tubular particles containing translation products of pre-S1, pre-S2 regions and the S gene were broken into constituent envelope polypeptides and immobilized on a solid support. Serums were absorbed with spherical particles containing translation products of pre-S2 region and the S gene, obtained from plasma positive for hepatitis B e antigen (HBeAg) and deprived of particles carrying pre-S1 product by an affinity column. They were then tested for the binding with tubular polypeptides fixed on a solid support, and the bound antibody representing anti-pre-S1 was detected by monoclonal antibody to human IgM/mu or IgG/gamma labeled with horseradish peroxidase. For the determination of anti-pre-S2, test serums were absorbed with spherical particles containing the product of the S gene, obtained from plasma positive for antibody to HBeAg and deprived of particles bearing pre-S2 product by an affinity column. They were then tested for the binding with polypeptides, fixed on a solid support, composed of products of pre-S2 region and the S gene. The assay was applied to the determination of anti-pre-S1 and anti-pre-S2 of IgM or IgG class in asymptomatic carriers and in persons who had recovered from infection with hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537138     DOI: 10.1016/0022-1759(86)90313-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Three envelope proteins of hepatitis B virus: large S, middle S, and major S proteins needed for the formation of Dane particles.

Authors:  K Ueda; T Tsurimoto; K Matsubara
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

Review 2.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection.

Authors:  Y Iwasaki; K Matsuura; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1990-08

4.  Assay of preS epitopes and preS1 antibody in hepatitis B virus carriers and immune persons.

Authors:  R Deepen; K H Heermann; A Uy; R Thomssen; W H Gerlich
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

5.  Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus.

Authors:  K Madalinski; B Burczynska; K H Heermann; A Uy; W H Gerlich
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Intrahepatic expression of pre-S1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta virus superinfection.

Authors:  C M Chu; Y F Liaw
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

7.  Clinical significance of low or negative titer of antibody to hepatitis B core antigen during the course of chronic hepatitis B virus infection in adolescents.

Authors:  K Matsuura; K Tobe; Y Iwasaki; H Ikeda; K Takahashi; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1993-02

8.  Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region.

Authors:  P Pontisso; M A Petit; M J Bankowski; M E Peeples
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.